ATP体外药敏试验指导的卵巢癌预见性化疗  

Predictive chemotherapy for ovarian cancer directed by ATP sensitivity test in vitro

作　　者：韩国荣[1] 沈玲[1] 余敏敏[1] 叶银英[2] 

机构地区：[1]东南大学医学院附属南京第二医院妇产科,江苏南京210003 [2]东南大学医学院现代医学实验中心,江苏南京210009

出　　处：《现代医学》2003年第3期148-150,共3页Modern Medical Journal

基　　金：南京市跨世纪人材科研基金 (960 1 6)

摘　　要：目的　探讨ATP体外药敏试验指导临床卵巢癌化疗的价值。方法　 86例卵巢癌患者中 ,5 7例在化疗前接受了ATP体外药敏试验。其中ATP敏感组 49例 ,根据药敏结果指导化疗 ;ATP耐药组 8例和对照组 2 9例则凭经验化疗。结果　ATP敏感组有效率为 75 5 % (3 7/4 9) ,ATP耐药组和对照组有效率分别为 0 (0 /8)及 5 5 2 % (16/2 9) ,差异有显著意义(P <0 .0 1)。本研究体外药敏和体内疗效的总符合率为 78 9%〔(3 7+ 8) /5 7〕。结论　ATP体外药敏试验指导临床卵巢癌化疗是可行的 。Objective To explore the value of the predictive chemotherapy for ovarian cancer directed by ATP sensitivity test in vitro.Methods Among the 86 patients with ovarian cancer,57 had received ATP sensitivity test before chemotherapy.According to the result of the ATP sensitivity test,49 patients in ATP sensitive group received chemotherapy.The other 8 patients in ATP resistant group and 29 patients in the control group were given chemotherapy according to clinical experience.Results The effectual rate in ATP sensitive group was 75.5%(37/49). There was statistically significant difference compared with 0(0/8) in the resistant group and 55.2%(16/29) in the control group.In vitro and in vivo,the overall coincident rate was 78.9%〔(37+8)/57〕.Conclusion The ATP sensitivity test in vitro can predict chemotherapy for ovarian cancer and give satisfactory results.

关 键 词：卵巢癌 预见性化疗 三磷酸腺苷 药敏试验 

分 类 号：R737.31[医药卫生—肿瘤] R730.53[医药卫生—临床医学]